Objective To investigate the effect of serum interleukin-6 (IL-6) level on long-term prognosis of intracoronary drug-eluting stent implantation. Methods A total of 246 patients who underwent drug-eluting stent implantation in our hospital from January 2014 to January 2015 were enrolled. According to the changes of IL-6 levels before and 1 year after surgery,patients were divided into two groups. The postoperative IL-6 elevation group (93 cases) and the IL-6 reduction group (153 cases). All patients underwent 3-year telephone follow-up and compared the incidence of major adverse cardiovascular events at 1 year,2 years,and 3 years. Results There was no significant difference in the incidence of cumulative adverse cardiovascular events between the two groups at 1 year postoperatively (P>0.05). At 2 years after operation,the cumulative target lesion revascularization was significantly higher in the IL-6-increased group than in the IL-6-lower group (P<0.05),but there was no statistically significant difference in the cumulative adverse cardiovascular events between the two groups (P>0.05). At 3 years after operation,the cumulative target vessel revascularization,cumulative adverse cardiovascular events,and cumulative incidence of cardiac death in the IL-6-increased group were significantly higher than those in the IL- 6-reduced group (P<0.05). Conclusion Compared with the serum IL-6-reduced group,the long-term prognosis of patients with elevated serum IL-6 after coronary stent-graft implantation was significantly poor.
Chinese Journal of Evidence-Based Cardiovascular Medicine
Drug-eluting stent implantation
Coronary heart disease